ADMA Biologics Inc (NASDAQ:ADMA) Director Eric I. Richman acquired 25,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was bought at an average price of $2.15 per share, with a total value of $53,750.00. Following the transaction, the director now directly owns 31,300 shares in the company, valued at $67,295. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.
ADMA Biologics Inc (ADMA) opened at $2.48 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26. ADMA Biologics Inc has a 1 year low of $2.01 and a 1 year high of $6.88.
ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.29). ADMA Biologics had a negative return on equity of 76.26% and a negative net margin of 35.00%. The company had revenue of $3.40 million during the quarter, compared to the consensus estimate of $3.52 million. sell-side analysts expect that ADMA Biologics Inc will post -2.25 EPS for the current fiscal year.
Separately, ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.